Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30596225 | 0.87 | KMT2A (0.49) | F2MEN1KMT2APOLBMAPT | |
| SCHEMBL4520971 | 0.84 | ROCK2 (0.52) | ROCK2ROCK1MEN1KMT2APOLB | |
| SCHEMBL27723719 | 0.84 | CYP17A1 (0.49) | CYP17A1F2ROCK2ROCK1MEN1 | |
| SCHEMBL4531740 | 0.83 | ROCK2 (0.49) | ROCK2ROCK1MEN1KMT2APOLB | |
| SCHEMBL13404759 | 0.82 | NOTUM (0.53) | ROCK2ROCK1 | |
| SCHEMBL4518662 | 0.81 | ROCK2 (0.47) | ROCK2ROCK1MEN1KMT2APOLB | |
| SCHEMBL24867525 | 0.81 | F2 (0.40) | CYP17A1F2 | |
| SCHEMBL4529314 | 0.81 | ROCK2 (0.42) | CYP17A1ROCK2ROCK1MEN1KMT2A | |
| SCHEMBL4533610 | 0.80 | ROCK2 (0.48) | ROCK2ROCK1MEN1KMT2APOLB | |
| SCHEMBL4526918 | 0.79 | HPGD (0.46) | ROCK2ROCK1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| CN-101253152-A | Amide derivatives as ROCK inhibitors | ASTELLAS PHARMA INC (JP) | 2008-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | CYP17A1 3015/4885F2 4565/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.